SlideShare a Scribd company logo
Transgenic CETP Dahl Salt-sensitive
(Tg53) Rat Model
“Is it promising enough?”
Victoria L. M. Herrera, M.D.
Associate Professor of Medicine
Section of Molecular Genetics
Whitaker Cardiovascular Institute
Boston University School of Medicine
700 Albany Street – W609, Boston MA 02118
vherrera@bu.edu
Tg53 rat model – “is it promising enough?”
Question analyzed –
• a provocative but necessary question posed by
Symposium organizers
• modeling the “vulnerable plaque” has been an
underestimated challenge
• a review of multi-species animal models of
atherosclerosis from the 1960s underscores this
challenge
Modeling vulnerable plaque – an underestimated challenge
Analysis of coronary artery
disease at end-stage
plq
hge
plq
eros’n
plq
fissure
plq
thombosis occlus’n
Pigeon: Carneau, Show Racer
* aortic root
nr + nr nr +
Monkey: a. Cynomolgus
b. African green
c. Rhesus
+
+
nr
nr
nr
nr
nr
nr
nr
nr
nr
nr
+
+
Pig: a. thiouracil + xrad’n
b. FHC: hyperLDL-emia
+
+
nr
nr
+
nr
some
some
+
+
Rabbit: WatanabeHHL
* coronary ostia
nr nr nr nr +
Mouse: ApoE/LDLr knockout nr nr nr nr +
Rat: Tg53 rat model + + + + +
[nr, not reported; +, present]
Elements of a “promising model”
Simulation of coronary artery disease
– plaque site
– disease course
– plaque progression
Model advantages as experimental system
– reproducibility
– duration to valid endpoints
– defined genetic background
– accessible phenotype manipulation
Model value and potential
– as investigative instrument
– as pre-clinical platform
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque site
 plaque predilection site = coronary arteries
 in contrast to: aortic root plaque predilection site in
mouse models described to date
Tg53 end-stage
plaques in proximal
right coronary artery
[PTAH stain, 40x
original mag]
RV
Ao
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
disease course
 risk factors consistent with human CHD
• hypertension exacerbates phenotype
• atherogenic lipid profile: increased total
cholesterol and triglyceride levels, low HDL,
increased VLDLc and VLDLtg, increased small
LDLc
• hyperlipidemia increases with age
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
disease course
 decreased survival compared with non-transgenic –
non-hyperlipidemic, hypertensive, Dahl S rat
controls on regular rat chow [Nat Med 5: 383, 1999; Mol
Med 7:831, 2001].
 “end-stage” simulates cardiac endpoints of CHD
• (+) cardio-respiratory distress
• (+) signs of heart failure
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque progression
 “culprit” plaque features: foam-cell rich, paucity of smcs, leukocyte
adhesion, intraplaque thrombi, erosion, plaque shoulder
susceptibility
Masson – trichrome stain 400x orig mag PTAH; 1000x orig
mag
Elements of a “promising model”
Masson – trichrome; 1000x orig
mag
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque progression
 “culprit plaque features: foam-cell rich, intraplaque hemorrhage,
paucity of smcs, lipid core > 1/3 of plaque volume
smc α-actin, Fast red im-stn; 400x
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque progression
 “culprit” plaque features: fibrin-positive thrombosis in
proximal coronary lesions; none detected in more distal
stable lesions
PTAH: fibrin(+) thrombus; prox lesion PTAH: distal stable lesion
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque progression
 recapitulates lesion heterogeneity of “culprit” plaques
associated with human acute coronary syndromes
PTAH: thick cap, smc-rich, but with
intraplq hge & thrombosis, IEL disrup’n
PTAH: reduced cap & smc; foam-cell
rich; + intraplq hge & thrombosis,
Elements of a “promising model”
Tg53 rat model: advantages as experimental system
 reproducibility and robustness of phenotype
• lipid profile: increased total cholesterol and
triglycerides predominantly in VLDL, low HDL
• “culprit” plaque phenotype in proximal right coronary
artery
• “stable” occlusive plaque in smaller coronary arteries
 reasonable duration to valid endpoints
• 6-9+ month range of proximal coronary plaque
development on regular rat chow: eccentric
macrophage-foam cell rich plaque which progresses to
“culprit” plaque at endstage
Elements of a “promising model”
Tg53 rat model: advantages as experimental system
 defined genetic background – eliminates
differential genetic susceptibility as confounder
• inbred Dahl salt-sensitive hypertensive rat strain
 accessible phenotype manipulation – onset and
course of hyperlipidemia and coronary artery
disease can be experimentally manipulated
• Western Type Diet (0.15% cholesterol) accelerates
onset and levels of hyperlipidemia
• low salt diet (0.0038% NaCl), which reduces level of
hypertension, attenuates coronary artery disease hence
increasing survival
Elements of a “promising model”
 Tg53 rat model: value and potential
 identical genetic background and ability to
regulate environmental factors allows well-
controlled in vivo studies for cross-talk
pathogenesis:
a. investigation of mechanisms of coronary
plaque development not possible in humans
b. methodical in vivo investigation of novel
intervention targets
c. maximization of genomic-based technologies
aimed at the investigation of mechanisms and
targets
Elements of a “promising model”
 Tg53 rat model: value and potential
 coronary-specific experimental design for
coronary artery-disease studies: with cumulative
evidence of vessel-specific genetic factors, the
Tg53 coronary-specific phenotype is key
 combinatorial modeling: well characterized
inbred rat strains allow cross-breeding for
interaction studies relevant to human disease
 hypertension
• diabetes
• obesity
Elements of a “promising model”
 Tg53 rat model: value and potential
 as investigative tool: invaluable new insight
distinct from that observed in current other models
– as a beginning,
1. prelude to culprit plaque: the eccentric macrophage
foam-cell rich lesion becomes the “culprit” plaque, thus
experimentally “capturing” the beginning of the
vulnerable plaque
2. differential pathway hypothesis: proximal vulnerable-
culprit coronary lesions develop distinct from more
distal stable coronary plaques
3. lesion heterogeneity paradigm: given identical genetic
background and environmental factors, lesion
heterogeneity at end-stage reflect stochastic endpoints
of a common pathogenic framework
Elements of a “promising model”
 Tg53 rat model: value and potential
 as pre-clinical platform
• identical genetic background
• regulated environmental factors
• robust coronary phenotype
• instrumentation accessibility
• rat physiological and pharmacological information
database
– allow continuity of comparative analysis for
successful new intervention and prevention
strategies
• ... can’t promise the world – but along with
other animal models, can together make a
better promise,
• but then again, which model can be
“promising enough” since even humans –
although they are the ultimate benchmarks –
make terrible models, if not the worst, for
human coronary artery disease ...

Tg53 rat model – “is it promising enough?”
Acknowledgment
• This work is supported by grants from the
National Institutes of Health and American
Heart Association.

More Related Content

Viewers also liked

126 micro array study for gene expression
126 micro array study for gene expression126 micro array study for gene expression
126 micro array study for gene expression
Society for Heart Attack Prevention and Eradication
 
Economics of screening for atherosclerosis final
Economics of screening for atherosclerosis finalEconomics of screening for atherosclerosis final
Economics of screening for atherosclerosis final
Society for Heart Attack Prevention and Eradication
 
257 inhibition of atherosclerosis in mice
257 inhibition of atherosclerosis in mice257 inhibition of atherosclerosis in mice
257 inhibition of atherosclerosis in mice
Society for Heart Attack Prevention and Eradication
 
031
031031
131 the evolution of coronary atherosclerosis
131 the evolution of coronary atherosclerosis131 the evolution of coronary atherosclerosis
131 the evolution of coronary atherosclerosis
Society for Heart Attack Prevention and Eradication
 
501 autoimmune disease
501 autoimmune disease501 autoimmune disease
115 genomic and proteomic screen
115 genomic and proteomic screen115 genomic and proteomic screen
115 genomic and proteomic screen
Society for Heart Attack Prevention and Eradication
 
Deteection of vulnerable atherosclerotic plaque by nis
Deteection of vulnerable atherosclerotic plaque by nisDeteection of vulnerable atherosclerotic plaque by nis
Deteection of vulnerable atherosclerotic plaque by nis
Society for Heart Attack Prevention and Eradication
 
Morrisett
MorrisettMorrisett
Definition of vulnerable plaque atlanta
Definition of vulnerable plaque atlantaDefinition of vulnerable plaque atlanta
Definition of vulnerable plaque atlanta
Society for Heart Attack Prevention and Eradication
 
112 macrophage uptake of cns1 1 d
112 macrophage uptake of cns1 1 d112 macrophage uptake of cns1 1 d
112 macrophage uptake of cns1 1 d
Society for Heart Attack Prevention and Eradication
 
Eas poster titles final
Eas poster titles finalEas poster titles final

Viewers also liked (13)

126 micro array study for gene expression
126 micro array study for gene expression126 micro array study for gene expression
126 micro array study for gene expression
 
Economics of screening for atherosclerosis final
Economics of screening for atherosclerosis finalEconomics of screening for atherosclerosis final
Economics of screening for atherosclerosis final
 
257 inhibition of atherosclerosis in mice
257 inhibition of atherosclerosis in mice257 inhibition of atherosclerosis in mice
257 inhibition of atherosclerosis in mice
 
031
031031
031
 
131 the evolution of coronary atherosclerosis
131 the evolution of coronary atherosclerosis131 the evolution of coronary atherosclerosis
131 the evolution of coronary atherosclerosis
 
501 autoimmune disease
501 autoimmune disease501 autoimmune disease
501 autoimmune disease
 
036 dogs heart
036 dogs heart036 dogs heart
036 dogs heart
 
115 genomic and proteomic screen
115 genomic and proteomic screen115 genomic and proteomic screen
115 genomic and proteomic screen
 
Deteection of vulnerable atherosclerotic plaque by nis
Deteection of vulnerable atherosclerotic plaque by nisDeteection of vulnerable atherosclerotic plaque by nis
Deteection of vulnerable atherosclerotic plaque by nis
 
Morrisett
MorrisettMorrisett
Morrisett
 
Definition of vulnerable plaque atlanta
Definition of vulnerable plaque atlantaDefinition of vulnerable plaque atlanta
Definition of vulnerable plaque atlanta
 
112 macrophage uptake of cns1 1 d
112 macrophage uptake of cns1 1 d112 macrophage uptake of cns1 1 d
112 macrophage uptake of cns1 1 d
 
Eas poster titles final
Eas poster titles finalEas poster titles final
Eas poster titles final
 

Similar to 041 transgenic cetp dahl salt sensitive (tg53) rat model

SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH Vets
 
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
Mohsin Maqbool
 
Telomeres, Telomerase, and TA-65
Telomeres, Telomerase, and TA-65Telomeres, Telomerase, and TA-65
Telomeres, Telomerase, and TA-65
telomerescience
 
Hodgkins lymphoma kiran
Hodgkins lymphoma   kiranHodgkins lymphoma   kiran
Hodgkins lymphoma kiran
Kiran Ramakrishna
 
V_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_GujralV_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_Gujral
EAFO1
 
Dr. Randall Prather - PRRS Resistant Pigs
Dr. Randall Prather - PRRS Resistant PigsDr. Randall Prather - PRRS Resistant Pigs
Dr. Randall Prather - PRRS Resistant Pigs
John Blue
 
Donor Selection: Unrealted donor transplant. Prof. Richard Champlin
Donor Selection: Unrealted donor transplant. Prof. Richard ChamplinDonor Selection: Unrealted donor transplant. Prof. Richard Champlin
Donor Selection: Unrealted donor transplant. Prof. Richard Champlin
spa718
 
Kennedy takotsubo qrw aug 2015
Kennedy takotsubo qrw aug 2015Kennedy takotsubo qrw aug 2015
Kennedy takotsubo qrw aug 2015
Martin Kennedy
 
Paediatric Cushing’s disease.pptx
Paediatric Cushing’s disease.pptxPaediatric Cushing’s disease.pptx
Paediatric Cushing’s disease.pptx
Dr Pushpender Khatana
 
Percutaneous coronary intervention by hossein
Percutaneous coronary intervention  by hosseinPercutaneous coronary intervention  by hossein
Percutaneous coronary intervention by hossein
Society for Heart Attack Prevention and Eradication
 
032 hossein eftekhari,md
032 hossein eftekhari,md032 hossein eftekhari,md
032 hossein eftekhari,md
032 hossein eftekhari,md032 hossein eftekhari,md
032 hossein eftekhari,md
SHAPE Society
 
2014 07 ismb personalized medicine
2014 07 ismb personalized medicine2014 07 ismb personalized medicine
2014 07 ismb personalized medicine
University of California, San Francisco
 
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Andrew Su
 
Big data exposome and pediatric outcomes
Big data exposome and pediatric outcomesBig data exposome and pediatric outcomes
Big data exposome and pediatric outcomes
Chirag Patel
 
J Immunol-2010-Yin-5828-34
J Immunol-2010-Yin-5828-34J Immunol-2010-Yin-5828-34
J Immunol-2010-Yin-5828-34
Chun-Yu Yen
 
Stem cell therapy : A hope to "No Hope Disorders" Diseased Dr. Sharda Jain
Stem cell therapy : A hope to "No Hope Disorders"  Diseased Dr. Sharda Jain Stem cell therapy : A hope to "No Hope Disorders"  Diseased Dr. Sharda Jain
Stem cell therapy : A hope to "No Hope Disorders" Diseased Dr. Sharda Jain
Lifecare Centre
 
Mast cell disorders
Mast cell disordersMast cell disorders
Presentation: TGA considerations for preclinical studies of cell therapy prod...
Presentation: TGA considerations for preclinical studies of cell therapy prod...Presentation: TGA considerations for preclinical studies of cell therapy prod...
Presentation: TGA considerations for preclinical studies of cell therapy prod...
TGA Australia
 
LEUKEMIA.pptx
LEUKEMIA.pptxLEUKEMIA.pptx
LEUKEMIA.pptx
Kiran Ramakrishna
 

Similar to 041 transgenic cetp dahl salt sensitive (tg53) rat model (20)

SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
 
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
 
Telomeres, Telomerase, and TA-65
Telomeres, Telomerase, and TA-65Telomeres, Telomerase, and TA-65
Telomeres, Telomerase, and TA-65
 
Hodgkins lymphoma kiran
Hodgkins lymphoma   kiranHodgkins lymphoma   kiran
Hodgkins lymphoma kiran
 
V_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_GujralV_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_Gujral
 
Dr. Randall Prather - PRRS Resistant Pigs
Dr. Randall Prather - PRRS Resistant PigsDr. Randall Prather - PRRS Resistant Pigs
Dr. Randall Prather - PRRS Resistant Pigs
 
Donor Selection: Unrealted donor transplant. Prof. Richard Champlin
Donor Selection: Unrealted donor transplant. Prof. Richard ChamplinDonor Selection: Unrealted donor transplant. Prof. Richard Champlin
Donor Selection: Unrealted donor transplant. Prof. Richard Champlin
 
Kennedy takotsubo qrw aug 2015
Kennedy takotsubo qrw aug 2015Kennedy takotsubo qrw aug 2015
Kennedy takotsubo qrw aug 2015
 
Paediatric Cushing’s disease.pptx
Paediatric Cushing’s disease.pptxPaediatric Cushing’s disease.pptx
Paediatric Cushing’s disease.pptx
 
Percutaneous coronary intervention by hossein
Percutaneous coronary intervention  by hosseinPercutaneous coronary intervention  by hossein
Percutaneous coronary intervention by hossein
 
032 hossein eftekhari,md
032 hossein eftekhari,md032 hossein eftekhari,md
032 hossein eftekhari,md
 
032 hossein eftekhari,md
032 hossein eftekhari,md032 hossein eftekhari,md
032 hossein eftekhari,md
 
2014 07 ismb personalized medicine
2014 07 ismb personalized medicine2014 07 ismb personalized medicine
2014 07 ismb personalized medicine
 
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
 
Big data exposome and pediatric outcomes
Big data exposome and pediatric outcomesBig data exposome and pediatric outcomes
Big data exposome and pediatric outcomes
 
J Immunol-2010-Yin-5828-34
J Immunol-2010-Yin-5828-34J Immunol-2010-Yin-5828-34
J Immunol-2010-Yin-5828-34
 
Stem cell therapy : A hope to "No Hope Disorders" Diseased Dr. Sharda Jain
Stem cell therapy : A hope to "No Hope Disorders"  Diseased Dr. Sharda Jain Stem cell therapy : A hope to "No Hope Disorders"  Diseased Dr. Sharda Jain
Stem cell therapy : A hope to "No Hope Disorders" Diseased Dr. Sharda Jain
 
Mast cell disorders
Mast cell disordersMast cell disorders
Mast cell disorders
 
Presentation: TGA considerations for preclinical studies of cell therapy prod...
Presentation: TGA considerations for preclinical studies of cell therapy prod...Presentation: TGA considerations for preclinical studies of cell therapy prod...
Presentation: TGA considerations for preclinical studies of cell therapy prod...
 
LEUKEMIA.pptx
LEUKEMIA.pptxLEUKEMIA.pptx
LEUKEMIA.pptx
 

More from Society for Heart Attack Prevention and Eradication

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
Society for Heart Attack Prevention and Eradication
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
Society for Heart Attack Prevention and Eradication
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
Society for Heart Attack Prevention and Eradication
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
Society for Heart Attack Prevention and Eradication
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
Society for Heart Attack Prevention and Eradication
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
Society for Heart Attack Prevention and Eradication
 
Vp watch2002
Vp watch2002Vp watch2002
Vp symposium31602
Vp symposium31602Vp symposium31602
Vpschoenhagen
VpschoenhagenVpschoenhagen

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 

Recently uploaded

Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"
AlexandraDiaz101
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
RESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiyaRESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiya
Bhavyakelawadiya
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
Gokuldas Hospital
 
KENT'S REPERTORY by dr niranjan mohanty.pptx
KENT'S REPERTORY by dr niranjan mohanty.pptxKENT'S REPERTORY by dr niranjan mohanty.pptx
KENT'S REPERTORY by dr niranjan mohanty.pptx
SravsPandu1
 
Local anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdfLocal anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdf
NarminHamaaminHussen
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
Gokuldas Hospital
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Get New Sim
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
DrGirishJHoogar
 
Nutritional deficiency disorder in Child
Nutritional deficiency disorder in ChildNutritional deficiency disorder in Child
Nutritional deficiency disorder in Child
Bhavyakelawadiya
 
13. PROM premature rupture of membranes
13.  PROM premature rupture of membranes13.  PROM premature rupture of membranes
13. PROM premature rupture of membranes
TigistuMelak
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
MuskanShingari
 
Pollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdfPollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdf
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
Gokuldas Hospital
 
What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?
Healthmedsrx.com
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 

Recently uploaded (20)

Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
RESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiyaRESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiya
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
 
KENT'S REPERTORY by dr niranjan mohanty.pptx
KENT'S REPERTORY by dr niranjan mohanty.pptxKENT'S REPERTORY by dr niranjan mohanty.pptx
KENT'S REPERTORY by dr niranjan mohanty.pptx
 
Local anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdfLocal anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdf
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
 
Nutritional deficiency disorder in Child
Nutritional deficiency disorder in ChildNutritional deficiency disorder in Child
Nutritional deficiency disorder in Child
 
13. PROM premature rupture of membranes
13.  PROM premature rupture of membranes13.  PROM premature rupture of membranes
13. PROM premature rupture of membranes
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
 
Pollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdfPollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdf
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
 
What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 

041 transgenic cetp dahl salt sensitive (tg53) rat model

  • 1. Transgenic CETP Dahl Salt-sensitive (Tg53) Rat Model “Is it promising enough?”
  • 2. Victoria L. M. Herrera, M.D. Associate Professor of Medicine Section of Molecular Genetics Whitaker Cardiovascular Institute Boston University School of Medicine 700 Albany Street – W609, Boston MA 02118 vherrera@bu.edu
  • 3. Tg53 rat model – “is it promising enough?” Question analyzed – • a provocative but necessary question posed by Symposium organizers • modeling the “vulnerable plaque” has been an underestimated challenge • a review of multi-species animal models of atherosclerosis from the 1960s underscores this challenge
  • 4. Modeling vulnerable plaque – an underestimated challenge Analysis of coronary artery disease at end-stage plq hge plq eros’n plq fissure plq thombosis occlus’n Pigeon: Carneau, Show Racer * aortic root nr + nr nr + Monkey: a. Cynomolgus b. African green c. Rhesus + + nr nr nr nr nr nr nr nr nr nr + + Pig: a. thiouracil + xrad’n b. FHC: hyperLDL-emia + + nr nr + nr some some + + Rabbit: WatanabeHHL * coronary ostia nr nr nr nr + Mouse: ApoE/LDLr knockout nr nr nr nr + Rat: Tg53 rat model + + + + + [nr, not reported; +, present]
  • 5. Elements of a “promising model” Simulation of coronary artery disease – plaque site – disease course – plaque progression Model advantages as experimental system – reproducibility – duration to valid endpoints – defined genetic background – accessible phenotype manipulation Model value and potential – as investigative instrument – as pre-clinical platform
  • 6. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) plaque site  plaque predilection site = coronary arteries  in contrast to: aortic root plaque predilection site in mouse models described to date Tg53 end-stage plaques in proximal right coronary artery [PTAH stain, 40x original mag] RV Ao
  • 7. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) disease course  risk factors consistent with human CHD • hypertension exacerbates phenotype • atherogenic lipid profile: increased total cholesterol and triglyceride levels, low HDL, increased VLDLc and VLDLtg, increased small LDLc • hyperlipidemia increases with age
  • 8. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) disease course  decreased survival compared with non-transgenic – non-hyperlipidemic, hypertensive, Dahl S rat controls on regular rat chow [Nat Med 5: 383, 1999; Mol Med 7:831, 2001].  “end-stage” simulates cardiac endpoints of CHD • (+) cardio-respiratory distress • (+) signs of heart failure
  • 9. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) plaque progression  “culprit” plaque features: foam-cell rich, paucity of smcs, leukocyte adhesion, intraplaque thrombi, erosion, plaque shoulder susceptibility Masson – trichrome stain 400x orig mag PTAH; 1000x orig mag
  • 10. Elements of a “promising model” Masson – trichrome; 1000x orig mag Tg53 rat model simulates human coronary heart disease (CHD) plaque progression  “culprit plaque features: foam-cell rich, intraplaque hemorrhage, paucity of smcs, lipid core > 1/3 of plaque volume smc α-actin, Fast red im-stn; 400x
  • 11. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) plaque progression  “culprit” plaque features: fibrin-positive thrombosis in proximal coronary lesions; none detected in more distal stable lesions PTAH: fibrin(+) thrombus; prox lesion PTAH: distal stable lesion
  • 12. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) plaque progression  recapitulates lesion heterogeneity of “culprit” plaques associated with human acute coronary syndromes PTAH: thick cap, smc-rich, but with intraplq hge & thrombosis, IEL disrup’n PTAH: reduced cap & smc; foam-cell rich; + intraplq hge & thrombosis,
  • 13. Elements of a “promising model” Tg53 rat model: advantages as experimental system  reproducibility and robustness of phenotype • lipid profile: increased total cholesterol and triglycerides predominantly in VLDL, low HDL • “culprit” plaque phenotype in proximal right coronary artery • “stable” occlusive plaque in smaller coronary arteries  reasonable duration to valid endpoints • 6-9+ month range of proximal coronary plaque development on regular rat chow: eccentric macrophage-foam cell rich plaque which progresses to “culprit” plaque at endstage
  • 14. Elements of a “promising model” Tg53 rat model: advantages as experimental system  defined genetic background – eliminates differential genetic susceptibility as confounder • inbred Dahl salt-sensitive hypertensive rat strain  accessible phenotype manipulation – onset and course of hyperlipidemia and coronary artery disease can be experimentally manipulated • Western Type Diet (0.15% cholesterol) accelerates onset and levels of hyperlipidemia • low salt diet (0.0038% NaCl), which reduces level of hypertension, attenuates coronary artery disease hence increasing survival
  • 15. Elements of a “promising model”  Tg53 rat model: value and potential  identical genetic background and ability to regulate environmental factors allows well- controlled in vivo studies for cross-talk pathogenesis: a. investigation of mechanisms of coronary plaque development not possible in humans b. methodical in vivo investigation of novel intervention targets c. maximization of genomic-based technologies aimed at the investigation of mechanisms and targets
  • 16. Elements of a “promising model”  Tg53 rat model: value and potential  coronary-specific experimental design for coronary artery-disease studies: with cumulative evidence of vessel-specific genetic factors, the Tg53 coronary-specific phenotype is key  combinatorial modeling: well characterized inbred rat strains allow cross-breeding for interaction studies relevant to human disease  hypertension • diabetes • obesity
  • 17. Elements of a “promising model”  Tg53 rat model: value and potential  as investigative tool: invaluable new insight distinct from that observed in current other models – as a beginning, 1. prelude to culprit plaque: the eccentric macrophage foam-cell rich lesion becomes the “culprit” plaque, thus experimentally “capturing” the beginning of the vulnerable plaque 2. differential pathway hypothesis: proximal vulnerable- culprit coronary lesions develop distinct from more distal stable coronary plaques 3. lesion heterogeneity paradigm: given identical genetic background and environmental factors, lesion heterogeneity at end-stage reflect stochastic endpoints of a common pathogenic framework
  • 18. Elements of a “promising model”  Tg53 rat model: value and potential  as pre-clinical platform • identical genetic background • regulated environmental factors • robust coronary phenotype • instrumentation accessibility • rat physiological and pharmacological information database – allow continuity of comparative analysis for successful new intervention and prevention strategies
  • 19. • ... can’t promise the world – but along with other animal models, can together make a better promise, • but then again, which model can be “promising enough” since even humans – although they are the ultimate benchmarks – make terrible models, if not the worst, for human coronary artery disease ...  Tg53 rat model – “is it promising enough?”
  • 20. Acknowledgment • This work is supported by grants from the National Institutes of Health and American Heart Association.